Weeks 17 through 20: 12.5 mg per week
Hepatic Uncommon (0.1% to 1%): Acute gallbladder disease (cholelithiasis, biliary colic, cholecystectomy) Hypersensitivity Common (1% to 10%): Hypersensitivity reactions (e.g., urticaria, eczema) Postmarketing reports : Anaphylaxis, angioedema Immunologic Very common (10% or more): Anti-drug antibodies (up to 51%) Common (1% to 10%): Neutralizing antibodies Local Common (1% to 10%): Injection site reactions Metabolic Very common (10% or more): Hypoglycemia (up to 19%), decreased appetite (up to 11%) Common (1% to 10%): Hyperglycemia Hypoglycemia (glucose level less than 54 mg/dL) occurred more frequently when this drug was used in combination with a sulfonylurea (up to 13% of patients in a clinical trial)
Patients on metformin alone had a mean HbA1c of 8.28%, despite being on at least 1,500 mg daily
Most side effects are digestive changes, but it is often mild, temporary, and tend to improve as your body adjusts to treatment
Significant Weight Loss: 12-24 Weeks As for most clinical trials that have looked at this medication, published data demonstrate that achieving meaningful weight reductions requires that the therapy be persisted for a period of 12 to 24 weeks
